Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval on July 16, 2026 advanced breast cancer Approved CELC Celcuity Deferred drug launch Falls gedatolisib launch Malignant neoplasm of breast Mutation PIK3CA gene Revtorpyk U.S. United States Food and Drug Administration +